SLGC - SomaLogic, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.3300
+0.1500 (+4.72%)
As of 03:53PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.1800
Open3.2100
Bid3.3100 x 2200
Ask3.3200 x 1000
Day's Range3.1500 - 3.3450
52 Week Range1.9800 - 6.1700
Volume751,275
Avg. Volume1,023,304
Market Cap625.857M
Beta (5Y Monthly)1.91
PE Ratio (TTM)N/A
EPS (TTM)-0.8100
Earnings DateAug 14, 2023 - Aug 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for SLGC

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    SomaLogic to Participate in the Jefferies Healthcare Conference

    BOULDER, Colo., May 24, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming Jefferies Healthcare Conference. SomaLogic management is scheduled to participate in a fireside chat on Wednesday, June 7, 2023, at 3:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the virtual session on the “Investors” section of the company’s website at: https://investors.somalogic.com/eve

  • GlobeNewswire

    SomaLogic Reports First Quarter 2023 Financial Results

    First quarter 2023 revenue of $20.4 million, representing a decrease of 11% year-over-year; excluding licensing, revenue increased 2% year-over-yearReiterating full year 2023 revenue guidance of $80-84 million Expense reduction initiatives on track and maintaining full year 2023 operating expense targetsCash and investments of $500.6 million, allowing for strategic optionality Management to host conference call today at 4:30pm ET BOULDER, Colo., May 11, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc.,

  • GlobeNewswire

    SomaLogic expands into China with groundbreaking Biostar Technology Limited Partnership

    SomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics marketSHANGHAI and BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Biostar Technology Limited will be the company’s first authorized site in China to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers. “We are delighted to be partnering with SomaLogic to expand the company’s global reach in Asia

  • GlobeNewswire

    SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers

    Two winners will be awarded 40 human plasma or serum samples to be processed on the SomaScan® Platform at Genomax’s Singapore lab SINGAPORE & BOULDER, Colo., May 07, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a global leader in proteomics technology, today announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore. This effort is SomaLogic’s first grant in the APAC region. The winners of the award will receive proteomic data from SomaLogic’s 7,000-plex assay, wh

  • Simply Wall St.

    Fewer Investors Than Expected Jumping On SomaLogic, Inc. (NASDAQ:SLGC)

    With a median price-to-sales (or "P/S") ratio of close to 4.4x in the Life Sciences industry in the United States, you...

  • GlobeNewswire

    SomaLogic to Announce First Quarter 2023 Financial Results on May 11, 2023

    BOULDER, Colo., April 20, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the first quarter 2023 after market close on Thursday, May 11, 2023. Management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the start of the call. A live

  • TipRanks

    ‘Too Cheap to Ignore’: Cathie Wood Snaps Up These 2 Stocks Under $5

    In the aftermath of last month’s failure of Silicon Valley Bank and the resulting banking crisis, economists and market experts are now turning their attention to the bigger picture, and unfortunately, the outlook is bleak. Cathie Wood, founder and head of ARK Investment, has pointed out that the velocity of money is slowing, and the odds of a ‘hard landing’ are rising. In her view, we’re more likely to see the economy take sharp downturn in the near future, caused by a confluence of high intere

  • GlobeNewswire

    SomaLogic Reports Fourth Quarter and Full Year 2022 Financial Results, Announces Director Appointments and Management Evolution

    Adam Taich, EVP Life Sciences, promoted to interim CEO with a focus on operational executionBoard transition adds industry veterans: Jason Ryan as Chairman; Tycho Peterson, Kathy Hibbs, and Tom Carey as Independent DirectorsFourth quarter 2022 revenue of $18.8 million; full year 2022 revenue of $97.7 million Full year 2023 revenue guidance of $80-84 million, reflecting 12-17% growth over 2022, excluding licensing revenue from New England Biolabs Substantial balance sheet provides flexibility wit

  • GlobeNewswire

    Oxford Population Health and SomaLogic deliver 28 million proteomic data points on China Kadoorie Biobank samples

    BOULDER, Colo., March 13, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, recently completed the 7,000-plex assay on and delivered data for 4,000 plasma samples from the China Kadoorie Biobank (CKB), one of the world’s largest prospective studies. The SomaLogic team provided more than 28 million data points from the assay which will be combined with other available genetic, lifestyle, anthropometric and health outcome data to address a range of research questions. Th

  • GlobeNewswire

    SomaLogic to Announce Fourth Quarter and Full Year 2022 Financial Results

    BOULDER, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on Tuesday, March 28, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes before the st

  • GlobeNewswire

    SomaLogic announces Certified Site expansion through world-class multiomics initiative with Group 42 Healthcare

    BOULDER, Colo., Jan. 31, 2023 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced the expansion of its SomaLogic™ Certified Site program through a recently-launched, world-class proteomics initiative with Group 42 Healthcare (G42), an artificial intelligence and cloud computing company. SomaLogic will become the sole provider of high-plex proteomics technology to G42. This initiative spans the United Arab Emirates (UAE) and Kingdom of Saud

  • GlobeNewswire

    SomaLogic Announces Preliminary Full Year 2022 Revenue and Provides Organizational and Strategic Updates

    Presenting at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 11:15 a.m. Pacific TimeBOULDER, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that preliminary, unaudited revenue for the full year 2022 is expected to be at the high end of its guidance range of $93 to $98 million, reflecting approximately 20% year-over-year revenue growth. In addition, SomaLogic is pleased to announce several organizat

  • GlobeNewswire

    SomaLogic to Participate in the 41st Annual J.P. Morgan Healthcare Conference

    BOULDER, Colo., Dec. 29, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, today announced that the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference. SomaLogic will present at the conference on Thursday, January 12, 2023 at 11:15 a.m. Pacific Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://investors.somalogic.com. About SomaLog

  • GlobeNewswire

    FonesLife offers the 7,000-plex SomaScan® Platform as Japan’s first SomaLogic™ Certified Site

    TOKYO and BOULDER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomic technology, announced today that Tokyo-based FonesLife Corporation, will be the first SomaLogic™ Certified Site in Japan. The new site will offer the 7,000-plex SomaScan® Assay in their labs and provide SomaScan data to their customers. By becoming a SomaLogic Certified Site, FonesLife can now run assays on SomaLogic’s SomaScan Platform—the largest commercially available proteomic platform—and acce

  • GlobeNewswire

    Proteomics labs worldwide can now access SomaLogic’s industry-leading 7,000-plex SomaScan® Assay with the Certified Site program

    BOULDER, Colo., Dec. 07, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today the full-scale global launch of the SomaLogic™ Certified Site program, which will allow institutions around the world to run the 7,000-plex SomaScan® Assay in their own labs. By becoming a SomaLogic Certified Site, labs can run assays on SomaLogic’s SomaScan® Platform—the largest commercially available proteomics platform—and accelerate their own research and generate revenue as

  • GlobeNewswire

    Study finds proteomic risk scores for cardiovascular disease from SomaSignal® Cardio DM™ tests could support physicians in managing patient outcomes

    BOULDER, Colo., Nov. 17, 2022 (GLOBE NEWSWIRE) -- In an upcoming randomized, controlled study enrolling 248 physicians, researchers are measuring whether SomaLogic’s SomaSignal® tests aid physicians in the risk stratification for cardiovascular disease of their patients. Researchers from the University of California, San Francisco (UCSF) are investigating if these physicians are more likely to prescribe high-risk patients with drugs to aid in blood glucose control, like SGLT2 inhibitors and GLP-

  • GlobeNewswire

    SomaLogic Reports Third Quarter 2022 Financial Results

    Third quarter 2022 revenue of $41.7 million, bringing year to date revenue to $78.8 million.Core life science revenue of $20.5 million, representing an increase of 2.9% year-over-year and 45.4% compared to the last quarter.On track to reduce operational expenses by $75 million through 2023. Raising 2022 full year revenue guidance to a range of $93 to $98 million, taking into account the $21.2 million in licensing royalty revenue recognized in the third quarter.Cash, cash equivalents, and short-t

  • GlobeNewswire

    SomaLogic Teams with Molecular Genomics to Bring the 7,000-Plex SomaScan® Platform to Asia

    SINGAPORE and BOULDER, Colo., Nov. 08, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Singapore-based Molecular Genomics, a Genomax Technologies company, will be the first site in Asia to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers. “We are honored to be able to partner with SomaLogic to bring the industry leading SomaScan Platform to the region,” said Genomax Technologies and Molecular Genomics Chief Execut

  • GlobeNewswire

    SomaLogic presents new research at American Heart Association Scientific Sessions that illustrates the power of proteomics in addressing cardiovascular disease

    SomaLogic and prominent research partners will lead five sessions about CVD and other leading causes of deathBOULDER, Colo., Oct. 31, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced findings from key studies demonstrating the broad and deep role proteomics plays in detecting cardiovascular risk, achieving optimal cardiometabolic health, and assessing the correlation of cardiovascular disease with other diseases that are among t

  • GlobeNewswire

    SomaLogic’s 7K SomaScan® Platform receives high marks in independent technical assessment by researchers at the National Institutes of Health

    BOULDER, Colo., Oct. 27, 2022 (GLOBE NEWSWIRE) -- In a recent paper published earlier this month in Nature Scientific Reports, researchers at the National Institutes of Health conducted what may be the largest technical assessment to date of the 7K SomaScan® Platform to measure its performance and to support the platform’s growing community of users. The researchers found the platform’s extensive proteome coverage, sensitivity and consistently low variability to be particular strengths, and desc

  • GlobeNewswire

    SomaLogic to Announce Third Quarter 2022 Financial Results

    BOULDER, Colo. and SAN DIEGO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will host a corresponding audio webcast beginning at 8:30 a.m. ET. Those interested in listening to the conference call should register online here. Participants are encouraged to register more than 15 minutes b

  • GlobeNewswire

    SomaLogic Announces the Appointment of Biotech Veteran Troy Cox as Executive Chairman of the Board of Directors

    BOULDER, Colo. and SAN DIEGO, Oct. 17, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced the appointment of current board member and biotech veteran Troy Cox as Executive Chair to the company’s Board of Directors. The current Chair, Chuck Lillis, will remain on the board. Changes are effective as of today, October 17, 2022. Mr. Cox brings over thirty years of experience in the life sciences and biopharmaceuticals industry to his

  • GlobeNewswire

    SomaLogic's Chief Medical Officer Steve Williams honored with C-Suite Award by the Denver Business Journal

    BOULDER, Colo., Sept. 26, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in AI data-driven proteomics technology, today announced that Chief Medical Officer Steve Williams, M.D., Ph.D., has been named a 2022 C-Suite Award winner by the Denver Business Journal. The honorees in the Denver Business Journal's 2022 C-Suite Awards program are executives who were evaluated by a team of third-party judges on the impact they have made on their organizations, industries and the greater commun

  • GlobeNewswire

    SomaLogic to Present at the Capital One Spatial Biology & Proteomics Summit

    BOULDER, Colo., Sept. 14, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that management will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28. Roy Smythe, M.D, SomaLogic’s Chief Executive Officer is scheduled to participate in two panel discussions. Proteomics “Everything You Wanted to Know, But Were Afraid to Ask”Executive Panel Discussion at 10:15 a.m.

  • GlobeNewswire

    SomaLogic to Present at Morgan Stanley 20th Annual Global Healthcare Conference

    BOULDER, Colo., Aug. 31, 2022 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the company will be participating in the upcoming Morgan Stanley 20th Annual Global Healthcare Conference in New York, New York. Roy Smythe, M.D, SomaLogic’s Chief Executive Officer is scheduled to participate in a fireside chat on Wednesday, September 14, 2022 at 12:20 p.m. Eastern Time. Interested parties may access a live and archived webcast of the present